Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Wugen

Main focus: Off-the-shelf cellular therapies for cancer treatment

Company stage: Clinical

Diseases: T-cell acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), head and neck cancer, melanoma

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: San Diego, CA, USA and St. Louis, MO, USA

Website: https://www.wugen.com/

Pipeline: https://www.wugen.com/pipeline/

Wugen is a privately held biotech company. The company focuses on developing CAR-T and natural killer (NK) cells to kill malignant T cells and solid tumours. Wugen uses CRISPR for the deletion of the T-cell receptor (TCR), which enables the use of T cells from healthy donors without the risk of graft-versus-host disease.

Tags

HashtagWUGEN Inc.

Company: Wugen
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine